Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
7.52
+0.09 (1.28%)
Apr 25, 2025, 12:36 PM EDT - Market open
Amneal Pharmaceuticals Revenue
In the year 2024, Amneal Pharmaceuticals had annual revenue of $2.79B with 16.73% growth. Amneal Pharmaceuticals had revenue of $730.52M in the quarter ending December 31, 2024, with 18.40% growth.
Revenue (ttm)
$2.79B
Revenue Growth
+16.73%
P/S Ratio
0.82
Revenue / Employee
$336,621
Employees
8,300
Market Cap
2.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
AMRX News
- 14 days ago - Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month - Business Wire
- 16 days ago - Amneal to Report First Quarter 2025 Results on May 2, 2025 - Business Wire
- 18 days ago - Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease - Business Wire
- 22 days ago - Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S. - Business Wire
- 24 days ago - Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - Business Wire
- 5 weeks ago - Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued - Seeking Alpha
- 6 weeks ago - Amneal to Participate at Upcoming Investor Conference - Business Wire
- 7 weeks ago - Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - Business Wire